This is placeholder text. To connect this element to content from your collection, select the element and click Connect to Data.
Customization
Integration of ToxGPS, ChemTunes and Corina technology into your chemoinformatics environment
Customization
Integration of ToxGPS, ChemTunes and Corina technology into your chemoinformatics environment
Customization
Integration of ToxGPS, ChemTunes and Corina technology into your chemoinformatics environment
training and consultancy for computational toxicology
M7(R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk
Guidance collection
2018
ICH M7, impurities, genotoxicity, QSAR, read-across
FDA
The synthesis of drug substances involves the use of reactive chemicals, reagents, solvents, catalysts, and other processing aids. As a result of chemical synthesis or subsequent degradation, impurities reside in all drug substances and associated drug products. While ICH Q3A Impurities in New Drug Substances (Revision 2) (Q3A) and Q3B(R2) Impurities in New Drug Products (Q3B) (Refs. 1 and 2) provide guidance for qualification and control for the majority of the impurities, limited guidance is provided for those impurities that are DNA reactive.